IBP-9414 for the Prevention of Necrotizing Enterocolitis

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 27, 2016

Primary Completion Date

August 7, 2017

Study Completion Date

August 7, 2017

Conditions
Necrotizing Enterocolitis
Interventions
DRUG

IBP-9414

DRUG

Placebo

Sterile water

Trial Locations (15)

11203

Kings County Hospital Center, Brooklyn

19102

Hahnemann University Hospital, Philadelphia

19141

Einstein Medical Center of Philadelphia, Philadelphia

27157

Wake Forest University Health Sciences, Winston-Salem

27710

Duke University Medical Center, Durham

32207

Wolfson Children´s Hospital, Jacksonville

32209

UF Health Jacksonville, Jacksonville

33136

Jackson Memorial Hospital, Miami

38301

Jackson Madison County General Hospital, Jackson

46601

Memorial Hospital of South Bend, South Bend

67214

Wesley Medical Center, Wichita

72202

Univ. Arkansas Medical Sciences, Little Rock

84057

Timpanogos Regional Hospital, Orem

90095

UCLA Medical Center, Los Angeles

32610-0296

University Florida Health, Gainesville

Sponsors
All Listed Sponsors
lead

Infant Bacterial Therapeutics

INDUSTRY

NCT02472769 - IBP-9414 for the Prevention of Necrotizing Enterocolitis | Biotech Hunter | Biotech Hunter